Literature DB >> 8387277

The hepatitis C virus encodes a serine protease involved in processing of the putative nonstructural proteins from the viral polyprotein precursor.

M R Eckart1, M Selby, F Masiarz, C Lee, K Berger, K Crawford, C Kuo, G Kuo, M Houghton, Q L Choo.   

Abstract

The hepatitis C virus (HCV) nonstructural protein 3 (NS3) domain has been predicted from sequence comparisons to represent a trypsin-like serine protease. By expressing wild-type and mutant HCV-1 cDNAs in transfected mammalian cells, we have identified putative nonstructural proteins 3 (72 kDa), 4 (10 kDa and 27 kDa) and 5 (58 kDa) and have shown that their processing from the viral polyprotein precursor is dependent on Ser1165 located in the proposed protease catalytic site. Data obtained from in vitro RNA translations indicate that unlike the processing of the NS2/NS3 junction, NS3/NS4 processing is dependent on Ser1165. In contrast to the situation for the related flaviviral NS3 proteases, the HCV NS3-mediated cleavage of the NS3/NS4 junction does not require the upstream NS2 domain and may not occur at dibasic sites.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8387277     DOI: 10.1006/bbrc.1993.1429

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  60 in total

1.  Isolation and characterization of monoclonal antibodies that inhibit hepatitis C virus NS3 protease.

Authors:  T Ueno; S Misawa; Y Ohba; M Matsumoto; M Mizunuma; N Kasai; K Tsumoto; I Kumagai; H Hayashi
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry.

Authors:  S Orrù; F Dal Piaz; A Casbarra; G Biasiol; R De Francesco; C Steinkühler; P Pucci
Journal:  Protein Sci       Date:  1999-07       Impact factor: 6.725

3.  Characterization of engineered hepatitis C virus NS3 protease inhibitors affinity selected from human pancreatic secretory trypsin inhibitor and minibody repertoires.

Authors:  N Dimasi; F Martin; C Volpari; M Brunetti; G Biasiol; S Altamura; R Cortese; R De Francesco; C Steinkühler; M Sollazzo
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

4.  Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity.

Authors:  A J Weiner; X Paliard; M J Selby; A Medina-Selby; D Coit; S Nguyen; J Kansopon; C L Arian; P Ng; J Tucker; C T Lee; N K Polakos; J Han; S Wong; H H Lu; S Rosenberg; K M Brasky; D Chien; G Kuo; M Houghton
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase.

Authors:  R Bartenschlager; L Ahlborn-Laake; K Yasargil; J Mous; H Jacobsen
Journal:  J Virol       Date:  1995-01       Impact factor: 5.103

6.  The hepatitis C virus NS4B protein can trans-complement viral RNA replication and modulates production of infectious virus.

Authors:  Daniel M Jones; Arvind H Patel; Paul Targett-Adams; John McLauchlan
Journal:  J Virol       Date:  2008-12-10       Impact factor: 5.103

7.  Kinetic and structural analyses of hepatitis C virus polyprotein processing.

Authors:  R Bartenschlager; L Ahlborn-Laake; J Mous; H Jacobsen
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

8.  Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins.

Authors:  C Failla; L Tomei; R De Francesco
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

9.  Hepatitis C virus polyprotein processing: kinetics and mutagenic analysis of serine proteinase-dependent cleavage.

Authors:  Y Tanji; M Hijikata; Y Hirowatari; K Shimotohno
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

10.  Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus.

Authors:  R Ray; A Khanna; L M Lagging; K Meyer; Q L Choo; R Ralston; M Houghton; P R Becherer
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.